468 PATENT ABSTRACTS

4871661 4871834

P R O C E S S F O R T E S T I N G T H E M O N O C L O N A L A N T I B O D I E S C A R C I N O G E N I C I T Y O F A S P E C I F I C T O C E A

M A T E R I A L O R T H E P R E S E N G E O F C A N C E R - I N D U C I N G Yuji Matsuoka, Masahide Kuroki, Sawara ku,

F A C T O R S I N A N E N V I R O N M E N T Fukuoka shi, Fukuoka ken, Japan

A process for producing monoclonal antibodies Thomas E Webb, Dorothy Schumm, Margaret specific to carcinoembryonic antigen (CEA), Hanausek-Walaszek, Zbigniew Walaszek, comprising immunizing a mammal with a first Raymond W Lang assigned to The Ohio State CEA to produce cells capable of producing anti- University Research Foundation bodies, collecting the cells from the mammal,

fusing the collected cells with the cells of a line of Materials can be screened for carcinogenic pro- myeloma of another mammal, selecting the thus- perties by administering them to test animals and obtained hybridoma cells on the basis of their assaying biological tissue, preferably plasma, for capacity to produce antibodies reactive with said the presence of a 60K cancer-associated first CEA, subjecting the thus-selected phosphoprotein. The test is applicable to a wide hybridoma cells to cloning, selecting the thus- range of chemically-diverse carcinogens and is obtained monoclones on the basis of the reac- not restricted to carcinogens having one par- tivities of monoclonal antibodies produced by ticular mode of action, them with at least one antigen selected from

CEAs other than said first CEA and CEA- related antigens of normal adult human origin, culturing the thus-obtained monoclones and recovering the desired monoclonal antibodies from the spent culture. The selection may pre- ferably be effected by radioimmunoassay using a marker antigen labelled with a radioactive sub-

4871677 stance. Monoclonal anti-CEA antibodies thus- produced have specific reactivity with the

M E T H O D O F C O L L E C T I N G A N D antigenic determinants of CEA molecules and thus may with advantage be used for various

A N A L Y Z I N G A S A M P L E O F clinical applications and fundamental medical B L O O D W H E N M O N I T O R I N G studies such as, for example, for determination

H E P A R I N T H E R A P Y of the concentration of CEA and CEA-related antigens.

Robert-Baugh, Cynthia Taylor assigned to Hemotec Inc

4873188 An inhibitor of platelet-related procoagulant ac- tivity is included in a collection medium into M E T H O D , M O N O C L O N A L which a whole blood sample is collected. The in- A N T I B O D Y , A N D M O N O C L O N A L hibitor prevents an initial drop in the recalcified A N T I B O D Y F R A G M E N T S F O R activated clotting time measured during an assay D E T E C T I N G H U M A N N O N - test conducted on the whole bJood sample collec- S M A L L C E L L L U N G ted in citrate in the medium. The discovery of the C A R C I N O M A S A N D C E L L L I N E problem of the initial drop in the activated clot- ting time and the solution of including the in- F O R P R O D U C I N G S U C H hibitor of the procoagulant activity is of A N T I B O D I E S considerable importance in heparin therapy, since the initial drop in the activated clotting Ingegerd Hellstrom, Joseph P Brown, Karl E time of heparinized blood is substantial. The in- Hellstrom, Diane Horn, Peter Linsley assigned hibitor can be included with a calcium chelating to Oncogen agent in the collection medium. Prostacylin and imidazole, which is an inhibitor of platelet The present invention is concerned with two thromboxane A2 synthesis, a r e effective in- novel monoclonal antibodies which define car- hibitors of this platelet-related procoagulant ac- bohydrate antigens associated with human non- tivity, small cell lung carcinomas ( NSCLC ) and